Skip to main content
. 2019 Aug 15;11(8):4696–4712.

Figure 5.

Figure 5

ERCs enhance the percentage of CD4+CD25+Foxp3+ Tregs via PD-L1 and induce the protection against colitis. Flow cytometric analysis of CD4+CD25+Foxp3+ Tregs was performed in different groups. A. Dot plot of CD4+CD25+Foxp3+ Tregs in vivo. B. Percentage of CD4+CD25+Foxp3+ Tregs in vivo (n=8 per group) and in vitro (n=6 per group). ERCs indicated ERCs-treatment. *ERCs indicated anti-PD-L1 pretreated ERCs treatment. *P<0.05.